Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

NCX1000

Known as: NCX 1000, NCX-1000 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study
OBJECTIVES:NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of… Expand
  • table 1
  • figure 2
  • table 2
  • figure 1
  • table 3
Is this relevant?
2007
2007
Combining ursodeoxycholic acid or its NO-releasing derivative NCX-1000 with lipophilic antioxidants better protects mouse hepatocytes against amiodarone toxicity.
Nonalcoholic steatohepatitis (NASH) is a common and potentially severe form of liver disease. This study aimed to determine the… Expand
Is this relevant?
2004
2004
Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice.
1. NCX-1000, (3alpha, 5beta, 7beta)-3,7-dihydroxycholan-24oic acid[2-methoxy-4-[3-[4-(nitroxy)butoxy]-3-oxo-1-propenyl]phenyl… Expand
Is this relevant?
2004
2004
NCX-1000: a liver-specific NO donor
Recent advances in the knowledge of the pathophysiology of portal hypertension show that cirrhotic liver exhibits endothelial… Expand
Is this relevant?
Review
2004
Review
2004
Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
Portal hypertension, a life threatening complication of liver cirrhosis, results from increased intrahepatic resistance and… Expand
Is this relevant?
2003
2003
NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver…
BACKGROUND/AIMS We studied whether acute administration of NCX-1000, a nitric oxide (NO)-releasing derivative of ursodeoxycholic… Expand
Is this relevant?
2003
2003
A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
BACKGROUND/AIMS A decreased intra-hepatic nitric oxide (NO) production participates on the pathogenesis of portal hypertension in… Expand
Is this relevant?
2003
2003
A New Synthetic Method of NCX-1000
To improve the reported synthetic route of NCX 1000 Using ferulic acid and 1,4 dibromobutane as the starting materials to prepare… Expand
Is this relevant?
2001
2001
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.
Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a… Expand
Is this relevant?
2001
2001
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity.
Caspases are key mediators in liver inflammation and apoptosis. In the present study we provide evidence that a nitric oxide (NO… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE